375 related articles for article (PubMed ID: 25376606)
1. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
4. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
6. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
8. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
10. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
11. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
Choo EF; Ng CM; Berry L; Belvin M; Lewin-Koh N; Merchant M; Salphati L
Cancer Chemother Pharmacol; 2013 Jan; 71(1):133-43. PubMed ID: 23053270
[TBL] [Abstract][Full Text] [Related]
12. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Alagesan B; Contino G; Guimaraes AR; Corcoran RB; Deshpande V; Wojtkiewicz GR; Hezel AF; Wong KK; Loda M; Weissleder R; Benes CH; Engelman J; Bardeesy N
Clin Cancer Res; 2015 Jan; 21(2):396-404. PubMed ID: 25348516
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
15. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
16. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
17. HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Jung KH; Yan HH; Fang Z; Son MK; Lee H; Hong S; Hong SS
Int J Oncol; 2014 Jul; 45(1):311-21. PubMed ID: 24819705
[TBL] [Abstract][Full Text] [Related]
18. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract][Full Text] [Related]
19. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
20. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
Wang MT; Fer N; Galeas J; Collisson EA; Kim SE; Sharib J; McCormick F
Nat Commun; 2019 Jul; 10(1):3055. PubMed ID: 31296870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
